Protein palmitoylation describes the hydrophobic post-translational modification of cysteine residues in certain proteins, and is required for the spatial organization and composition of cellular membrane environments. Certain palmitoylated proteins are processed by acyl protein thioesterase (APT) enzymes, which catalyze thioester hydrolysis of palmitoylated cysteine residues. Inhibiting APT enzymes disrupts Ras trafficking and attenuates oncogenic growth signaling, highlighting these enzymes as potential therapeutic targets. As members of the serine hydrolase enzyme family, APT enzymes can be assayed by fluorophosphonate activity-based protein profiling (ABPP) methods, allowing rapid profiling of inhibitor selectivity and potency. In this review, we discuss recent progress in the development of potent and selective inhibitors to APT enzymes, including both competitive and non-competitive chemotypes. These examples highlight how ABPP methods integrate with medicinal chemistry for the discovery and optimization of inhibitors in complex proteomes.
Introduction
Protein palmitoylation describes the post-translational attachment of a long-chain fatty acid to a cysteine residue 1 widespread role for such a hydrophobic modification. Due to the unstable thioester linkage, protein palmitoylation undergoes steady hydrolysis in cells, generally with a half-life of less than a few hours. Unlike static modifications like protein prenylation or myristoylation, protein palmitoylation provides a unique mechanism to reversibly regulate the membrane association of modified proteins. Indeed, dynamic palmitoylation of oncogenic HRas is required to mediate cell transformation 9 . Furthermore, activation of Ras or the G-protein Gα s stimulates palmitoylation turnover 10, 11 , suggesting palmitoylation dynamics may be an essential trigger in the activation or deactivation of distinct signaling pathways. In this model, protein palmitoyl thioesterases catalyze the de-palmitoylation and release of certain proteins from the plasma membrane, potentially attenuating membrane-coupled signaling pathways (Figure 1 ). The released proteins can then undergo re-palmitoylation by endomembrane-bound DHHC palmitoyl-transferases, restoring palmitoylation and resetting the cycle.
Given the evidence that HRas participates in an acylation/deacylation cycle 12 , a putative HRas thioesterase termed acyl protein thioesterase (APT1) was identified from soluble rat liver fractions 13 . This enzyme was previously characterized as lysophospholipase I (LYPLA1) 14 , but has several hundred-fold higher activity as a protein thioesterase 13 . APT1 removes palmitate from diverse palmitoyl protein substrates in vitro 13, 15 . Genetic deletion of the yeast homologue of APT1 shows a minor decrease in the turnover of palmitate on Gα s , yet has no defects in growth, mating, or deacylation of other palmitoylated proteins 16 . Despite these results, lysates from APT1 mutant yeast lack in vitro Gα s palmitoyl protein thioesterase activity 16 . Importantly, deletion of APT1 has no effect on lysophosphatidylcholine (LPC) hydrolysis activity, suggesting it is not a functional lysophospholipase 16 .
A second lysophospholipase II (APT2), is 68% homologous to APT1 17 , but surprisingly is slightly more efficient than APT1 at de-palmitoylating semi-synthetic NRas 18 . The axonal protein GAP-43 or HRas are more rapidly de-palmitoylated after APT2 over-expression 19 . Phylogenic analysis shows that invertebrates evolved only one APT enzyme, while vertebrates evolved two (APT1 and APT2). (Figure 2 ). Both APT1 and APT2 have themselves been identified as palmitoylated proteins 7, 20 , although the predicted palmitoylation site is not conserved in canine APT1 or invertebrate APTs. In mammalian neurons, APT1-mRNA is translationally repressed by a synaptic microRNA complex 21, 22 . Upon glutamate stimulation, the repressive complex is degraded to allow local translation of APT1 in synaptic spines 22 . APT1 expression induces a reduction in spine volume potentially by de-palmitoylating Gα 13 and reducing synaptic RhoA activation 21 . In addition, a recent in vivo RNAi screen identified APT2 as a candidate regulator of oncogenic HRas-dependent malignancy 23 . A third more distant homologue lysophospholipaselike 1 (LYPLAL1) contains a narrow substrate-binding pocket unable to accommodate longchain fatty acids 24 , and genetic studies support a role in obesity 25 . Overall, APT enzymes represent candidate protein palmitoyl thioesterases, but little is known about their substrates or dependence on upstream signals.
To address the proteome-wide dynamics and the contribution of enzymatic de-palmitoylation,
we recently applied non-radioactive bioorthogonal labeling approaches to selectively enrich palmitoylated proteins with enhanced turnover dynamics. This approach uses the commercially available fatty acid analogue 17-octadecynoic acid, which upon exogenous addition, is efficiently incorporated into endogenous sites of protein palmitoylation 2, 26 . After sufficient labeling, harvested cell lysates are conjugated to biotin-azide by copper-catalyzed click chemistry for subsequent streptavidin enrichment and mass spectrometry annotation. Using "pulse-chase" labeling methods, we profiled de-palmitoylation dynamics in mouse T-cells. Cells were first labeled with 17-ODYA, then after some time "chased" with excess palmitic acid with or without the non-selective lipid-like serine hydrolase inhibitor hexadecylfluorophosphonate (HDFP) 5 . This hydrophobic mechanism-based covalent inhibitor targets approximately 20 serine hydrolases characterized by their common preference for lipid-like substrates, including APT1
and APT2, but not LYPLAL1. We hypothesized that any candidate thioesterase is likely a serine hydrolase inhibited by HDFP. Quantitative proteomic analysis identified a subpopulation (<10%) of palmitoylated proteins that undergo rapid cycling mediated by one or more serine hydrolases targeted by HDFP 5 . This subset includes Ras family GTPases, G-proteins, and scaffolding proteins implicated in malignancy. This data confirms that enzymes functionally contribute to palmitoylation hydrolysis in cells, and HDFP inhibition is sufficient to block any enzymemediated palmitoylation turnover. Furthermore, given the relatively small subset of oncogenic signaling and scaffolding proteins, inhibiting de-palmitoylation may perturb key signaling pathways involved in malignancy.
APT enzymes are members of the α/β-hydrolase family of serine hydrolases 27 . 28, 29 , as well as modulating the membrane association of the estrogen receptor in hippocampal slices 30 . APT inhibition also enhances invasion of the parasitic protozoan T.gondii into human cells 31, 32 , suggesting unique regulation across evolution. In this review, we describe each reported APT inhibitor chemotype, including details regarding potency, selectivity, and biological evaluation. This includes a discussion on the application of competitive activity-based protein profiling (ABPP) methods to profile inhibitor selectivity and target occupancy in biological systems 33 .
Benzodiazepinediones
Early efforts towards the development of APT1 inhibitors were rationally designed based on substrate mimicry of a dually palmitoylated and farnesylated peptide (Figure 3) . A peptideimitating benzodiazepinedione core was fused to S-farnesyl cysteine methyl ester and an acyl- β-lactones β-lactone serine hydrolase inhibitors are best characterized by the over-the-counter weight loss drug tetrahydrolipstatin (THL or Orlistat) 35 . Originally identified as a natural product from
Streptomyces toxytricini
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, THL is representative of diverse bacterial β-lactones with functional roles as bacterial effectors. Upon oral delivery, THL is a mechanism-based inhibitor of several digestive lipases that acts by preventing fatty acid intestinal absorption. After nucleophilic attack of the lactone ester and ring opening, the subsequent acyl-enzyme hydrolysis is slow, rendering the enzyme predominantly in an inactive state 37 ( Figure 4A) . In order to discover novel APT1
inhibitors, a series of β-lactone derivatives were synthesized and profiled against APT1, leading to the discovery of the chiral acyl-β-lactone Palmostatin B (IC 50 = 5.4 nM) 28, 38 ( Figure 4B ).
Palmostatin B is readily membrane-permeable, and directly reacts with APT1 and APT2 as both a substrate and an inhibitor in live cells . Lysates were labeled with the alkynyl probes, conjugated to a tri-functional rhodamine/biotin-azide by copper-catalyzed click chemistry, enriched with streptavidin, and analyzed by in-gel fluorescence or mass spectrometry to identify candidate target proteins. These experiments confirmed APT1 and APT2 as major Palmostatin M targets, but also identified other serine hydrolases including the lysosomal thioesterase PPT1 and retinoid-inducible serine carboxypeptidase (RISC). While these compounds are exceptionally potent, non-specific inhibition and poor drug-like properties limit the application of these probes for in vivo studies.
Boronic Acids
In order to discover new chemotypes that inhibit APT enzymes, an immobilized library of <15,000 natural products and inhibitors was assayed for APT binding 39 . In this approach, inhibitors were covalently attached to glass using a trifluoromethylaryldiazirine photocrosslinking system, and then incubated with recombinant GST-fusions of APT1 or APT2. 
Triazole Ureas
Significant progress has been made in the development of selective serine hydrolase inhibitors through optimization of carbamates, leading to analogues with exquisite selectivity and potency as covalent probes 41 . Despite considerable effort, carbamates fail to reach a broad subset of serine hydrolases, including APT enzymes 42 . During efforts to explore novel covalent inhibitor scaffold of serine hydrolases, N-heterocyclic ureas were identified as a new chemotype for serine hydrolase inhibitor development 43 . Both carbamates and N-heterocyclic ureas undergo nucleophilic attack by the active-site nucleophilic serine, leading to formation of a nonhydrolysable carbamylated acyl-intermediate. These inhibitors are bioavailable, selective within the serine hydrolase enzyme family, and maintain activity both in vitro and in vivo 43, 44 .
Furthermore, a facile, convergent synthesis of triazole ureas accelerated the development of selective sub-nanomolar, in vivo active, selective inhibitors for acyl peptide hydrolase (APEH), as well as low nanomolar inhibitors of PAFAH2 and ABHD11 43 with limited medicinal chemistry efforts.
The development of triazole urea inhibitors is reinforced by guided medicinal chemistry using competitive fluorosphosphonate (FP) ABPP probes 33, 45 . In this assay, a complex proteome is mixed with a triazole urea analogue to achieve enzyme inhibition. Next, a reporter-tagged FPprobe is added that irreversibly reacts with all active serine hydrolases. Accordingly, any reduction in probe labeling corresponds to inhibition. Typically, the FP-tetramethylrhodamine (FP-TAMRA) is used for rapid gel-based analysis of both the potency and selectivity of a candidate inhibitor across all active serine hydrolases in a specific cell line or tissue isolate. For less abundant enzymes, quantitative analysis is performed using FP-biotin, followed by streptavidin enrichment and mass spectrometry annotation 43 . Rather than optimize for potency towards a specific target, this approach provides a simple assay to guide medicinal chemistry efforts primarily on selectivity.
Triazole urea libraries were synthesized by click chemistry of alkynyl variants with azide, followed by conjugation to diverse carbamoyl chlorides 43 . This two-step approach leads to regioisomers at the N2 (major) and N1 (minor) positions, which may potentially have differential inhibitory properties 44 . After identification of a candidate triazole urea lead for APT1, an . These inhibitors retain potency and selectivity in live cells with no observed toxicity.
Despite significant effort, little selectivity was achieved against the unannotated hydrolase ABHD11. This is less of a concern, since highly selective analogues targeting ABHD11 can be used as control probes 43 .
The parasitic protozoan T.gondii is a close relative to the malaria parasite P.falciparum, where proteomics studies have annotated hundreds of palmitoylated proteins including many required for infectivity 47 . In order to explore the potential of APT inhibition in the parasitic life Separate HTS screens were performed for APT1 and APT2, yielding hit rates of 0.156% and 0.380%, respectively 46, 51 . Each hit compound was re-tested in a confirmatory screen, which validated 69% APT1 inhibitors, and 66% APT2 inhibitors. This list was then manually filtered to exclude non-selective compounds identified in similar HTS assays for the serine hydrolases RBBP9 and PME1, and the cysteine-dependent enzyme GSTO 54 . In total, 91 APT1, 61 APT2, and 95 dual APT1/APT2 inhibitors were selected for in-gel ABPP confirmatory analysis. This filtered group of inhibitors included one triazole urea, but largely converged to a common (>1/3) piperazine amide chemotype (Figure 9 ). This motif bears striking similarity to triazole ureas, since each contain a five-membered ring (furan, thiophene, or triazole) linked across an amide/urea with a N-heterocycle. Furthermore, due to the large diversity of the library, a structure-activity relationship emerged, identifying APT1 inhibitors with extensions from the piperazine arm, and APT2 inhibitors with hydrophobic extensions off the thiophene arm.
Surprisingly, many of the inhibitors were selective for a specific APT isoform, an elusive property not found with other chemotypes. Overall, the most potent inhibitors were characterized in a fluorogenic substrate assay, providing K i values in the 200 -300 nM range, a surprising success for leads taken directly from the screening library. Interestingly, gel-based competitive ABPP shows stark differences in potency between the APT1 and APT2 compounds, yet steady-state kinetic analyses yielded effectively similar K i values. These findings suggest APT inhibitor's potency is derived primarily from its small K off value, and highlight how such nonequilibrium assays can improve selection for compounds with improved residency times.
Competitive assays with aliphatic FP-TAMRA proceeded to completion quickly under standard conditions, making it difficult to capture the optimal kinetic window for reversible inhibition competition 51 . To circumvent this problem, competitive ABPP assays were performed using a less reactive hydrophilic probe, FP-PEG-TAMRA. This probe is a less optimal substrate for APT enzymes, slowing the reaction kinetics enough to assay active site competition. Such findings have significant implications for competitive ABPP selectivity assays with reversible inhibitors, since different enzymes may react with ABPP probe variants with distinct kinetic windows.
For both APT1 and APT2, a small library of <10 analogues were assayed to establish a preliminary structure-activity relationship 51 . For the APT2 lead inhibitor, the para-(methoxyphenyl)piperazine arm was intolerant to substitutions in the ortho and meta positions.
Further modifications on the thiophene arm were more tolerant, suggesting opportunities for further optimization. Importantly, the (o-methoxyphenyl)piperazine analogue completely lost activity, providing an non-reactive control analogue. For the APT1 inhibitor, a similar negative control compound was identified with an α-methyl substitution at the amide linkage. Inhibitor selectivity was confirmed by gel-based competitive ABPP, but also by SILAC-ABPP, a quantitative mass spectrometry method to quantify inhibitor occupancy with increased sensitivity 43 . This approach confirmed isoform selective inhibition across the serine hydrolase enzyme family for each lead inhibitor. These experiments demonstrate how competitive ABPP methods can be used to profile reversible inhibitors in complex proteomes, although the relative reactivity of each enzyme towards the probe may vary. Therefore, when using competitive ABPP methods to assay reversible inhibitors, it is important to recognize that variable ABPP probe reaction rates can skew observed selectively profiles.
In order to validate target occupancy in vivo, each lead inhibitor injected into mice 
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